Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 56

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 56
---
 Familial Intrahepatic Cholestasis                                           Japan         Approved (Mar 2025)  
  TAK-999 3                                  GalNAc based RNA interference (RNAi) (injection)                     Peptide/oligonucleotide      Alpha-1 antitrypsin-deficiency associated liver disease                                 U. S.         P-III                
  TAK-279                                    TYK2 inhibitor (oral)                                                Small molecule               Psoriasis                                                                               Global        P-III                
                                                                                                                                               Psoriatic arthritis                                                                     Global        P-III                
                                                                                                                                               Crohn’s disease                                                                         -             P-II (b)             
                                                                                                                                               Ulcerative colitis                                                                      -             P-II (b)             
  TAK-079                                    Anti-CD38 monoclonal antibody (injection)                            Biologic and other           Immune thrombocytopenia                                                                 Global        P-III                
                                                                                                                                               Immunoglobulin A nephropathy                                                            -             P-I                  
  TAK-227/ZED1227 4                          Transglutaminase 2 inhibitor (oral)                                  Small molecule               Celiac disease                                                                          -             P-II (b)             

Table of Contents

  Development code      Type of Drug                                                     Modality                     Indications / additional formulations      Country/      Stage  
  TAK-101 5             Tolerizing Immune Modifying nanoParticle (TIMP) (injection)      Biologic and other           Celiac disease                             -             P-II   
  TAK-004               Peptide agonist (injection)                                      Peptide/oligonucleotide      Nausea and Vomiting                        -             P-I    

____________

Notes:

(1) Partnership with KM Biologics.

(2) Partnership with Mirum Pharmaceuticals.

(3) Partnership with Arrowhead Pharmaceuticals

(4) Partnership with Zedira and Dr. Falk Pharma. Dr. Falk Pharma leads development.

(5) Partnership with COUR Pharmaceuticals.

Neuroscience

In Neuroscience, Takeda is focusing its R& D investments on potentially transformative treatments for neurological and neuromuscular diseases of high unmet need and building its innovative pipeline by leveraging internal expertise and external collaborations. Takeda Neuroscience’s core focus is orexin biology, rare neurology and neurodegeneration diseases. We are advancing a portfolio of tailored therapies designed to unlock the full power of orexin (i. e., oveporexton (TAK-861), TAK-360) to redefine